Norovirus Vaccine

About CyanVac

CyanVac is a clinical-stage biotech advancing a pipeline of intranasal vaccines based on its proprietary PIV5 viral vector platform. Its lead programs target COVID-19 and RSV, both in clinical trials, with preclinical work in pandemic flu, norovirus, and Lyme disease. The company's strategy focuses on generating robust mucosal immunity to potentially block infection and transmission, addressing key limitations of injectable vaccines. CyanVac operates as a private entity and appears to be pre-revenue, leveraging its platform for both proprietary programs and through its affiliate, Blue Lake Biotechnology.

Therapeutic Areas